Organon (OGN) Deferred Taxes (2020 - 2026)
Organon (OGN) recorded quarterly Deferred Taxes of $3.0 million in Q1 2026, down 90.0% quarter-over-quarter from $30.0 million in Q4 2025, and up 117.65% on a YoY basis from $1.4 million in Q1 2025.
Organon (OGN) Deferred Taxes (2020 - 2026) Analysis & Trends
Organon's Deferred Taxes history runs 7 years deep, the most recent figure standing at $3.0 million for Q1 2026.
- In Q1 2026, Deferred Taxes rose 117.65% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $83.0 million (up 145.6% YoY), while the FY2025 annual figure was $63.0 million, up 139.37% from the prior year.
- Deferred Taxes was $3.0 million for Q1 2026 at Organon, down from $30.0 million in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $40.0 million in Q3 2025 to a low of -$489.0 million in Q4 2023.
- Historically, Deferred Taxes has averaged -$36.3 million across 5 years, with a median of $3.0 million in 2023.
- Biggest YoY gain for Deferred Taxes was 400.0% in 2024; the steepest drop was 2550.0% in 2024.
- A 5-year view of Deferred Taxes shows it stood at -$20.0 million in 2022, then sank by 2345.0% to -$489.0 million in 2023, then jumped by 102.04% to $10.0 million in 2024, then soared by 200.0% to $30.0 million in 2025, then slumped by 90.0% to $3.0 million in 2026.
- The last three Deferred Taxes figures came in at $3.0 million (Q1 2026), $30.0 million (Q4 2025), and $40.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,134,969.93 Bn | 92,134,964.97 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,027.45 Bn | 1,022.17 Bn | 16.22 Bn | 1.48 Bn |
| 3 | Johnson & Johnson | 559.08 Bn | 537.03 Bn | 15.96 Bn | 159.00 Mn |
| 4 | AbbVie | 394.75 Bn | 385.40 Bn | 10.78 Bn | 137.00 Mn |
| 5 | Merck | 295.12 Bn | 289.47 Bn | 12.09 Bn | -315.00 Mn |
| 6 | Amgen | 186.65 Bn | 174.61 Bn | 5.87 Bn | -176.00 Mn |
| 7 | Gilead Sciences | 159.22 Bn | 151.50 Bn | 5.52 Bn | 179.00 Mn |
| 8 | Pfizer | 146.00 Bn | 133.23 Bn | -1.21 Bn | -12.00 Mn |
| 9 | Bristol Myers Squibb | 113.22 Bn | 102.77 Bn | 8.07 Bn | 161.00 Mn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | 3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.00 Mn |
| Dec 31, 2025 | 30.00 Mn |
| Sep 30, 2025 | 40.00 Mn |
| Jun 30, 2025 | 10.00 Mn |
| Mar 31, 2025 | -17.00 Mn |
| Dec 31, 2024 | 10.00 Mn |
| Sep 30, 2024 | -196.00 Mn |
| Jun 30, 2024 | 21.00 Mn |
| Mar 31, 2024 | 5.00 Mn |
| Dec 31, 2023 | -489.00 Mn |
| Sep 30, 2023 | 8.00 Mn |
| Jun 30, 2023 | -7.00 Mn |
| Mar 31, 2023 | 3.00 Mn |
| Dec 31, 2022 | -20.00 Mn |
| Sep 30, 2022 | -9.00 Mn |
| Jun 30, 2022 | -5.00 Mn |
| Mar 31, 2022 | -4.00 Mn |
| Dec 31, 2021 | -76.00 Mn |
| Sep 30, 2021 | -41.00 Mn |
| Jun 30, 2021 | -146.00 Mn |